HER2 amplification in gastroesophageal adenocarcinoma correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization

American Journal of Clinical Pathology

Volumn 137, Issue 4, 2012, Pages 583-594

  Radu, Oana M ^a   Foxwell, Tyler ^b   Cieply, Kathleen ^a   Navina, Sarah ^a   Dacic, Sanja ^a   Nason, Katie S ^b   Davison, Jon M ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Esophagus; FISH; Fluorescence in situ hybridization; HER2; Image analysis; Immunohistochemistry; Stomach

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; HER2 PROTEIN, HUMAN;

ARTICLE; CANCER ADJUVANT THERAPY; CENTROMERE; CHROMOSOME 17; DIGITAL IMAGING; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL CARCINOMA; GENE AMPLIFICATION; GENE LOCUS; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; PRIORITY JOURNAL; SCORING SYSTEM; SCREENING TEST; STOMACH CANCER; ADENOCARCINOMA; AGED; ESOPHAGUS TUMOR; FEMALE; GENETICS; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84860589791     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPXQVS6YGHPDCY     Document Type: Article

References (25)

1. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135:55-62.
2. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB -related gene in a human mammary carcinoma. Science. 1985;229:974-976. (Pubitemid 16248488)
3. Yokota J, Yamamoto T, Miyajima N, et al.Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene. 1988;2:283-287. (Pubitemid 18085309)
4. Flejou JF, Paraf F, Muzeau F, et al.Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol. 1994;47:23-26. (Pubitemid 24057743)
5. Hu Y, Bandla S, Godfrey TE, et al.HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma [published online ahead of print April 1, 2011]. Mod Pathol. 2011;24:899-907.doi:.
6. Ishikawa T, Kobayashi M, Mai M, et al.Amplification of the c-erbB -2 (HER-2/neu) gene in gastric cancer cells: detection by fluorescence in situ hybridization. Am J Pathol. 1997;151:761-768. (Pubitemid 27385608)
7. Slamon DJ, Leyland-Jones B, Shak S, et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
8. Bang YJ, Van Cutsem E, Feyereislova A, et al., ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
9. Hofmann M, Stoss O, Shi D, et al.Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805. (Pubitemid 351724903)
10. United States Food and Drug Administration. Full Prescribing Information for Trastuzumab. 2010. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 103792s5250lbl.pdf. Accessed August 13, 2011.
11. European Medicines Agency. Committee for Medicinal Products for Human Use Post-Authorisation Summary of Positive Opinion for Herceptin. 2009. http://www.ema.europa.eu/pdfs/human/opinion/Herceptin-82246709en.pdf. Accessed August 13, 2011.
12. College of American Pathologists. HER2 Testing Guidelines and Resources. 2011. http://www.cap.org/apps/cap.portal?-nfpb=true&cntvwrPtlt- actionOverride=%2Fportlets%2FcontentViewer%2Fshow&-windowLabel= cntvwrPtlt&cntvwrPtlt%7BactionForm.contentReference%7D= committees%2Fimmunohistochemistry%2Fher2-index.html&-state= maximized&-pageLabel=cntvwr. Accessed August 11, 2011.
13. Ruschoff J, Dietel M, Baretton G, et al.HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299-307.
14. Seethala RR, Dacic S, Cieply K, et al.A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol. 2010;34:1106-1121.
15. Wolff AC, Hammond ME, Schwartz JN, et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
16. Tanner M, Hollmen M, Junttila TT, et al.Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273-278. (Pubitemid 40309309)
17. Reichelt U, Duesedau P, Tsourlakis M, et al.Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20:120-129. (Pubitemid 44967957)
18. Brien TP, Odze RD, Sheehan CE, et al.HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol. 2000;31:35-39. (Pubitemid 30054384)
19. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2011;58:383-394.
20. Bang YJ, Chung HC, Sawaki A, et al.HER2-positivity rates in advanced gastric cancer (GC): results from a large international phase III trial [abstract]. J Clin Oncol. 2008;26:219S. Abstract 4526.
21. Schoppmann SF, Jesch B, Friedrich J, et al.Expression of HER-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010;34:1868-1873.
22. Mayr D, Heim S, Werhan C, et al.Comprehensive immunohistochemical analysis of HER-2/neu oncoprotein overexpression in breast cancer: HercepTest (DAKO) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Arch. 2009;454:241-248.
23. Takehana T, Kunitomo K, Kono K, et al.Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002;98:833-837. (Pubitemid 34286677)
24. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5:63-69. (Pubitemid 38821193)
25. Rauser S, Weis R, Braselmann H, et al.Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res. 2007;13:5115-5123. (Pubitemid 47502079)